share_log

Roth Capital Downgrades Humanigen to Neutral, Lowers Price Target to $2

Benzinga Real-time News ·  Jul 13, 2022 09:48

Roth Capital analyst Tony Butler downgrades Humanigen (NASDAQ:HGEN) from Buy to Neutral and lowers the price target from $13 to $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment